Literature DB >> 21659727

Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia.

Michael Nagler1, M Gregor, W A Wuillemin.   

Abstract

We present 2 patients with hyperferritinemia, increased liver iron and hemochromatosis-associated HFE genotypes. At diagnosis, both patients had chronic anemia that prevented initiation of phlebotomy. Iron chelation with deferasirox proved to be a safe and effective means of substantially lowering ferritin levels.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21659727     DOI: 10.1159/000328039

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

1.  Juvenile Hemochromatosis: Rheumatic Manifestations of 2 Sisters Responding to Deferasirox Treatment. A Case Series and Literature Review.

Authors:  Jubran Alqanatish; Banan Alsowailmi; Haneen Alfarhan; Albandari Alhamzah; Talal Alharbi
Journal:  Open Access Rheumatol       Date:  2021-01-15

Review 2.  Chelation therapy in liver diseases of childhood: Current status and response.

Authors:  Jayendra Seetharaman; Moinak Sen Sarma
Journal:  World J Hepatol       Date:  2021-11-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.